BackLigaChem Biosciences Overview

LigaChem Biosciences EBIT

LigaChem Biosciences's EBIT is $-230B, below the Healthcare sector average of $1.9T.

Get informed when a big investor buys or sells

+ Follow

Quarterly EBIT

-$50.56B
↓ 227.33% YoY

As of Sep 30, 2026

Annual EBIT (TTM)

-$233.22B
↓ 515.87% YoY

Trailing 12 months ending Sep 30, 2026

Average EBIT (Comparison Companies)

EBIT History

EBIT Comparison

Annual EBIT Growth Rate (%)

Annual EBIT Growth (Absolute)

LigaChem Biosciences (141080.KQ) FAQ

LigaChem Biosciences posts a EBIT of $-230B as of September 2026. That compares with $56B in the prior-year period — down 515.9% year over year. That is below the Healthcare sector average of $1.9T. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, LigaChem Biosciences's EBIT was $56B. The latest reading is $-230B — a 515.9% year-over-year decrease (period ending September 2026). Use the history and growth charts on this page for a longer lookback.

For Healthcare stocks, a EBIT near $1.9T is typical. LigaChem Biosciences's $-230B is lower that level. That is roughly 112.0% below the sector mean. Whether that is a warning or an opportunity depends on growth outlook and other fundamentals shown elsewhere on Stockcircle.

EBIT is one piece of LigaChem Biosciences's financial statement story. At $-230B, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for 141080.KQ's EBIT usually means three checks: (1) trend versus prior periods, (2) level versus peers (average $1.9T), and (3) consistency with growth and profitability. This page covers the first two; LigaChem Biosciences's other metric pages and overview cover the third.